Regulation of L-type calcium channels in GH4 cells via A1 adenosine receptors.
Identification of A1 adenosine receptors (A1Rs) in a tumor cell line derived from rat pituitary (GH4 cells) was performed by ligand binding and immunological experiments. Subsequently, the involvement of A1Rs in the regulation of calcium conductance was studied in these cells. The agonist N6-(R)-(2-phenylisopropyl)adenosine (R-PIA) did not modify the intracellular calcium basal levels, whereas it inhibited the increase produced by 15 mM KCl depolarization. The antagonist 1,3-dipropyl-8-cyclopentylxanthine led to the opening of voltage-dependent cell surface calcium channels in the absence of exogenous KCl. The channels were of the L type because the effect was abolished by calciseptine and by verapamil. These results suggest that endogenous adenosine exerts a tonic inhibitory effect on calcium transport. This was confirmed by the high adenosine concentration found in cell supernatants (up to 1 microM) and by the calcium mobilization produced by exogenously added adenosine deaminase. In depolarizing conditions, the calcium peak in the presence of adenosine deaminase was reduced when cells were preincubated with R-PIA, thus suggesting that A1R activation regulates the intensity of depolarization. These results demonstrate that adenosine is an important regulator of the physiological state of pituitary tumor cells by modulating, in an autocrine manner, the activity of L-type voltage-dependent calcium channels.
Zapata
R
R
Departament de Bioquímica i Biologia Molecular, Facultat de Química, Universitat de Barcelona, Catalonia, Spain.
Navarro
A
A
Canela
E I
EI
Franco
R
R
Lluis
C
C
Mallol
J
J
D000241:Adenosine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D000243:Adenosine Deaminase / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism*; D002460:Cell Line; D004546:Elapid Venoms / Q000494:pharmacology; D007425:Intracellular Membranes / Q000378:metabolism; D010902:Pituitary Gland / Q000166:cytology / Q000378:metabolism*; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000502:physiology*; D014700:Verapamil / Q000494:pharmacology; D014970:Xanthines / Q000378:metabolism / Q000494:pharmacology
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D004546:Elapid Venoms; D018047:Receptors, Purinergic P1; D014970:Xanthines; C047235:N-(1-methyl-2-phenylethyl)adenosine; C067971:calciseptine; D011189:Potassium Chloride; C051360:1,3-dipropyl-8-cyclopentylxanthine; D014700:Verapamil; D000243:Adenosine Deaminase; D000241:Adenosine; D002118:Calcium